Jason P. Butler

Level 1 Ned Hanlon Building, Butterfield Street
Herston, QLD 4029, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Pembrolizumab as first therapy for elderly or comorbid patients with classical Hodgkin lymphoma: Results of the phase 2 PLIMATH trial.

Pembrolizumab as first therapy for elderly or comorbid patients with classical Hodgkin lymphoma: Results of the phase 2 PLIMATH trial.

Journal: British journal of haematology

Published: July 15, 2026

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.

Journal: British journal of haematology

Published: November 24, 2025

Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.

Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 15, 2025

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 18, 2025

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia.

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia.

Journal: Frontiers in oncology

Published: November 28, 2024

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

Journal: EBioMedicine

Published: March 24, 2024

Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma.

Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma.

Journal: Internal medicine journal

Published: February 13, 2024

Supporting Cancer Survivors Following Treatment for Non-Hodgkin's and Hodgkin's Lymphoma: A Pilot Study Assessing the Feasibility and Process Outcomes of a Nurse-Led Intervention.

Supporting Cancer Survivors Following Treatment for Non-Hodgkin's and Hodgkin's Lymphoma: A Pilot Study Assessing the Feasibility and Process Outcomes of a Nurse-Led Intervention.

Journal: Seminars in oncology nursing

Published: November 28, 2023

Granulocyte transfusion supportive care for prolonged cytopenias post CD19 CAR T cell therapy.

Granulocyte transfusion supportive care for prolonged cytopenias post CD19 CAR T cell therapy.

Journal: Transfusion

Published: November 21, 2023

Quantifying skin cancer risk following allogeneic haematopoietic cell transplant in Queensland, Australia.

Quantifying skin cancer risk following allogeneic haematopoietic cell transplant in Queensland, Australia.

Journal: Bone marrow transplantation

Published: August 02, 2023

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.

Journal: Blood

Published: June 23, 2023

A randomised trial of topical polaprezinc to prevent oral mucositis in patients undergoing haematopoietic stem cell transplantation (ToPaZ study).

A randomised trial of topical polaprezinc to prevent oral mucositis in patients undergoing haematopoietic stem cell transplantation (ToPaZ study).

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: June 04, 2023

Showing 1-12 of 44

Last Updated: 09/26/2026